BCAX
Bicara Therapeutics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 20 to Apr 27 ▼ 3 days of insider sells: $691.6K by 3 insiders, avg $23.29
- May 15 to May 21 ▼ 3 days of insider sells: $742.1K by 3 insiders, avg $20.22
- May 21 FDA: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differenti…
- Jul 2 Contract: Bicara Therapeutics Announces Inducement Grants under Nasd…
- Jul 8 to Jul 10 ▼ 3 days of insider sells: $1.9M by 3 insiders, avg $28.84
- Aug 10 ▼ 3 insiders sell $1.2M at $27.97
- Aug 11 Bicara Therapeutics reported Q2 2026 results with a net loss of $0.8…
- Aug 14 Contract: Bicara Therapeutics Announces Inducement Grant under Nasda…
- Sep 8 ▼ 1 insider sell $400.7K at $22.90
- Oct 5 Contract: Bicara Therapeutics Announces Inducement Grants under Nasd…
- Oct 30 ▼ Goldman Sachs downgrades
- Nov 4 Activist stake: Bicara Therapeutics Announces Inducement Grants under Nasd…
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $4.9M.
- InstitutionsBULLISH
Q3 2026: 22 added (0 new), 7 trimmed or exited.
- AnalystsBULLISH
18 of 20 rate it Buy or better. Median target $34.50 (+244%).
- EstimatesFLAT
Current-quarter EPS estimate −$0.848 → −$0.861 over 90 days. 7 up, 3 down in 30 days.
- Short sellersSTEADY
Short interest −4.2% to 9.86M shares. 3.8 days to cover, ≈14.9% of shares.
- TrendDOWNTREND
40% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | ADD | $23.7M |
| JPMORGAN CHASE & CO | TRIM | $13.3M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $12.2M |
| Jump Financial, LLC | DOUBLED | $4.3M |
| CITIGROUP INC | DOUBLED | $3.6M |
| TD ASSET MANAGEMENT INC | TRIM | $3.3M |
| Hudson Bay Capital Management LP | ADD | $3.1M |
| UBS Group AG | DOUBLED | $2.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
20 analystsPrice is inside the target range. Median implies +244%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 10, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Nov 10, 2026 | Stifel MAINTAIN | Buy |
| Nov 10, 2026 | BTIG MAINTAIN | Buy |
| Oct 30, 2026 | Goldman Sachs DOWNGRADE | Sell |
| Oct 29, 2026 | Wedbush MAINTAIN | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Cohlhepp Ryan President, COO & Interim CEO Sep 8, 2026 | EXERCISE | $66.3K |
Cohlhepp Ryan President, COO & Interim CEO Sep 8, 2026 | SELL | $80.7K |
Cohlhepp Ryan President, COO & Interim CEO Sep 8, 2026 | SELL | $320.1K |
Larson Jennifer Chief Financial Officer Aug 12, 2026 | AWARD | 285,000 sh |
Mazumdar Claire Chief Executive Officer Aug 10, 2026 | EXERCISE | $37.9K |
Mazumdar Claire Chief Executive Officer Aug 10, 2026 | SELL | $279.8K |
Cohlhepp Ryan President and COO Aug 10, 2026 | EXERCISE | $71.1K |
Hyep Ivan Chief Financial Officer Aug 10, 2026 | EXERCISE | $47.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.86 | -$0.97–-$0.47 | -4.8% | $0.00 |
| Next Q | -$1.01 | -$1.19–-$0.61 | -17.7% | $0.00 |
| Current FY | -$3.63 | -$3.89–-$2.65 | -7.2% | $0.00 |
| Next FY | -$3.89 | -$5.33–-$1.86 | -10.6% | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
20 filings · 6 press releases · 1 bullish · 2 bearish · 2 mixed · 15 neutral- NEUTRAL PRESS-RELEASENov 9, 2026
Bicara Therapeutics reported Q3 2026 net loss of $71.2M ($1.04 per share), wider than the $36.3M…
The wider-than-expected loss and higher cash burn reflect the ramp-up of the pivotal trial. The key catalyst is the FORTIFI-HN01 interim analysis in mid-2027. Monitor enrollment updates and any…
- NEUTRAL INST-CLUSTERNov 4, 2026
Three asset managers (Strs Ohio, Alps Advisors, Dimensional Fund Advisors) added to their BCAX…
The buying is from passive/index-oriented asset managers (Dimensional, Alps, Strs Ohio), not high-conviction active funds. Without insider buying or a clear catalyst, this cluster carries limited…
- NEUTRAL PRESS RELEASENov 4, 2026
Bicara Therapeutics granted a new employee a non-qualified stock option to purchase 50,000 shares…
This is a routine inducement grant for a new hire with no immediate read-through for the stock. Monitor upcoming clinical data readouts for ficerafusp alfa in head and neck squamous cell carcinoma.
- NEUTRAL SC 13G/AOct 7, 2026
T. Rowe Price Investment Management, Inc. filed an amendment to its Schedule 13G, disclosing a…
Monitor future 13G/H filings for further reductions below 5% or conversion to 13D if the fund's intent changes. The 4.2% stake is below the 5% threshold, so further decreases may not require…
All BCAX filing & press-release reports (26)
- PRESS-RELEASE reportNov 9, 2026
- INST-CLUSTER reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- SC 13G/A reportOct 7, 2026
- PRESS-RELEASE reportOct 5, 2026
- INST-CLUSTER reportSep 22, 2026
- 8-K reportAug 25, 2026
- CLUSTER reportAug 12, 2026
- PRESS-RELEASE reportAug 14, 2026
- CLUSTER reportAug 12, 2026
- PRESS-RELEASE reportAug 11, 2026
- 8-K reportAug 11, 2026
- CLUSTER reportJul 14, 2026
- INST-CLUSTER reportJun 11, 2026
- CLUSTER reportMay 26, 2026
- 8-K reportMay 11, 2026
- PRESS-RELEASE reportMay 4, 2026
- CLUSTER reportApr 20, 2026
- DEFA14A reportApr 27, 2026
- CLUSTER reportApr 15, 2026
- CLUSTER reportApr 15, 2026
- PRESS-RELEASE reportApr 3, 2026
- CLUSTER reportMar 16, 2026
- PRESS-RELEASE reportMar 23, 2026
- CLUSTER reportMar 16, 2026
- PRESS-RELEASE reportMar 4, 2026